Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 10 Jan 2018 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 25 Jan 2017 Planned End Date changed from 31 Dec 2017 to 1 Jan 2019.